Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Go back to Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1222.94 -9 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1231.94 | 52 Week High | $88.16 | |||
| Open | $1230.65 | 52 Week Low | $67.88 | |||
| Day High | $1238.00 | P/E | 283.09 | |||
| Day Low | $1210.01 | EPS | $4.32 | |||
| Volume | 614,705 | |||||
